IL1A alleles associate with a virological response to  antiretroviral therapy in HIV patients beginning  therapy with advanced disease.
Among Australians treated for advanced HIV disease, a suboptimal virological response was associated with allele 2 at interleukin 1 alpha (IL1A)-889 and IL1A+4845. This is confirmed and investigated using patients from AIDS Clinical Trials Group study 384 (n=532). Among non-African-American patients with CD4 T-cell count of< or = 100 cells/microl at baseline, IL1A+4845(*)TT was associated with poor virological outcome (P=0.03). Differences were smaller with higher baseline CD4 T-cell counts. IL1A-889 and IL1A+4845 were not in linkage disequilibrium in African-American patients, and IL1A+4845(*)T did not affect outcome.
Price
Patricia
P
School of Pathology and Laboratory Medicine, Universityof Western Australia, Nedlands, Western Australia, Australia. patricia.price@uwa.edu.au
James
Ian
I
D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D005260:Female; D008040:Genetic Linkage; D015658:HIV Infections / Q000188:drug therapy / Q000235:genetics*; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D053582:Interleukin-1alpha / Q000235:genetics*; D008297:Male; D012367:RNA, Viral / Q000235:genetics*
D053582:Interleukin-1alpha; D012367:RNA, Viral